Novartis, Roche and GlaxoSmithKline all returned for the series B round, having already supported a $22m series A round for the Harvard spinout in 2015.

Novartis, Roche and GlaxoSmithKline all returned for the series B round, having already supported a $22m series A round in 2015.

BridgeBio Pharma participated in a series B round for its subsidiary Eidos Therapeutics, which is working on treatments for a family of rare genetic diseases known as ATTR.

Optum has led a series A round for LetsGetChecked, which enables users to take medical tests at home.

Reflexion Medical, partially based on research at UChicago, secured the Rise Fund as lead investor, with Pfizer and Johnson & Johnson returning.

David Clifton will deploy his healthcare expertise in big data and machine learning as Drayson solidifies its Oxford digital health connections.

Malin has returned to support an oversubscribed series B round, led by Longitude Capital.

Legend Capital-backed Axonics Modulation Technologies has secured $40.1m, with $20.1m raised as equity and $20m in a credit facility supplied by Silicon Valley Bank.